Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation

Fresh arterial tissue generates an unstable substance (prostaglandin X) which relaxes vascular smooth muscle and potently inhibits platelet aggregation. The release of prostaglandin (PG) X can be stimulated by incubation with arachidonic acid or prostaglandin endoperoxides PGG₂ or PGH₂. The basal release of PGX or the release stimulated with arachidonic acid can be inhibited by previous treatment with indomethacin or by washing the tissue with a solution containing indomethacin. The formation of PGX from prostaglandin endoperoxides PGG₂ or PGH₂ is not inhibited by indomethacin. 15-hydro-peroxy arachidonic acid (15-HPAA) inhibits the basal release of PGX as well as the release stimulated by arachidonic acid or prostaglandin endoperoxides (PGG₂ or PGH₂). Fresh arterial tissue obtained from control or indomethacin treated rabbits, when incubated with platelet rich plasma (PRP) generates PGX. This generation is inhibited by treating the tissue with 15-HPAA. A biochemical interaction between platelets and vessel wall is postulated by which platelets feed the vessel wall with prostaglandin endoperoxides which are utilized to form PGX. Formation of PGX could be the underlying mechanism which actively prevents, under normal conditions, the accumulation of platelets on the vessel wall.     

Accelerative autoactivation of prostaglandin biosynthesis by PGG2.

Cyclooxygenase catalysis is stimulated by its product, PGG₂, and by other lipid hydroperoxides. The endoperoxide, PGH₂, was not stimulatory. The results provide a direct demonstration of an essential role for lipid hydroperoxides in prostaglandin biosynthesis, and show how the biosynthetic intermediate PGG₂ has a positive accelerative effect.     

Prostaglandin endoperoxides IV. Effects on smooth muscle

The effect on smooth muscle of the endoperoxides PGG₂ and PGH₂, which are intermediates in prostaglandin biosynthesis, was studied in different systems $\text{in vitro}$ and $\text{in vivo}$. On gastrointestinal smooth muscle (gerbil colon, rat stomach) PGG₂ and PGH₂ produced contractions comparable to those of PGE₂ and PGF_2a whereas contractions elicited on vascular (rabbit aorta) and airway (guinea-pig trachea) smooth muscle were considerably greater than those of PGE₂ and PGF_2a respectively. On intravenous injection into guinea-pigs PGG₂ and PGH₂ caused a triphasic change in blood pressure and were 8–10 times more effective than PGF_2a in producing an increase in tracheal insufflation pressure. When given as aerosols the unstable endoperoxides were less effective than PGF_2a. It is concluded that the endoperoxides are potent smooth muscle stimulants and that they are more effective than their degradation products (PGD₂, PGE₂, PGF_2a) in some systems.     

Some biological effects of prostaglandin endoperoxide analogs.

The effects of two methano-epoxy analogs of the prostaglandin endoperoxides PGG₂ and PGH₂ were tested on human platelets and rabbit aorta strips. One of these analogs, 9α, 11α-methano-epoxy-15- hydroxy-prosta-5, 13-dienoic acid, was 3.7 times more potent than the endoperoxide, PGG₂, as aggregating agent and was 6.2 times more active than PGH₂ in eliciting contractions of the isolated rabbit aorta. The analog initiated the platelet release reaction, but was less active than the endoperoxide in this respect. Furthermore, the release of ¹⁴C-serotonin induced by this analog was inhibited by indomethacin, which indicated that generation of endoperoxide was required.The corresponding 9α, 11α, epoxy-methano-analog was less active than the 9α, 11α, methano-epoxy analog in the test systems employed.     

The major product of PGG2 metabolism by aortic microsomes is 6, 15-dioxo-PGF1α

Incubations of PGG₂ with aortic microsomes yielded two products which were not formed in boiled enzyme control, one of which was 6-oxo-PGF_1α. The major metabolite was identified by gas-liquid chromatography-mass spectrometry as 6,15-dioxo-PGF_1α. Thus, unlike PGH₂, PGG₂ is probably converted to 15-hydroperoxy PGI₂ which subsequently decomposes to 6,15-dioxo-PGF_1α.     

Imidazole: A selective inhibitor of thromboxane synthetase

Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A₂ by platelet microsomes (IC₅₀: 22 μg/ml; determined by bioassay). The inhibitor is selective, for prostaglandin cyclo-oxygenase is only affected at high doses. Radiochemical data confirms that imidazole blocks the formation of ¹⁴C-thromboxane B₂ from ¹⁴C-PHG₂. Several imidazole analogues and other substances were tested but only 1-methyl-imidadole was more potent that imidazole iteself. The use of imidazole of inhibit thromboxane formation could help to elucidate the role of thromboxanes in physiology or pathophysiology.     

Reaction mechanism of prostaglandin E2 biosynthesis and its modeling

The reaction mechanism of PGE₂ biosynthesis was investigated by a detailed examination of the cyclo-oxygenase and PGE₂-isomerase activities in acetone-pentane powder (microsomal fraction of ram seminal vesicular glands). Two main types of inactivating process were recognized in the reaction system. One type was due to irreversible inactivation caused by the oxidizing agent [O]^·_X released through the reduction of PGG₂ to PGH₂, while the other type was due to reversible inhibition which was supposed to be derived from the precursor arachidonic acid (AA). This inhibitor was found to block the activities of both cyclooxygenase and PGE₂-isomerase, and to compete with the substrates AA and PGH₂. Although no significant substrate inhibition was observed, arachidonic acid was slightly inhibitory toward PGE₂-isomerase.     

Radical scavenging as the mechanism for stimulation of prostaglandin cyclooxygenase and depression of inflammation by lipoic acid and sodium iodide

Certain radical-trapping reducing agents have been shown to stimulate prostaglandin biosynthesis (1–6) and to depress phorbol myristate acetate-induced mouse ear edema (16). The increased prostaglandin synthesis resulted from influences on the cyclooxygenase. To ascertain whether these alterations were due to direct interaction with the enzyme or to indirect scavenging of the oxidant released during PGG₂ reduction, we report the effects of lipoic acid and sodium iodide.Both of these agents stimulated the enzymatic oxygenation of arachidonic acid, increased the reduction of PGG₂ to PGH₂, quenched the EPR signal induced by arachidonic acid and depressed mouse ear edema. In addition to discovering two unusual antiinflammatory agents, we have confirmed that materials with entirely different structures can have identical effects on the cyclooxygenase, suggesting indirect stimulation of this enzyme due to trapping of the oxidant.     

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides

Prostaglandin (PG) endoperoxides (PGG₂ and PGH₂) contract arterial smooth muscle and cause platelet aggregation. Microsomes from pig aorta, pig mesenteric arteries, rabbit aorta and rat stomach fundus enzymically transform PG endoperoxides to an unstable product (PGX) which relaxes arterial strips and prevents platelet aggregation. Microsomes from rat stomach corpus, rat liver, rabbit lungs, rabbit spleen, rabbit brain, rabbit kidney medulla, ram seminal vesicles as well as particulate fractions of rat skin homogenates transform PG endoperoxides to PGE- and PGF- rather than to PGX-like activity.PGX differs from the products of enzymic transformation of prostaglandin endoperoxides so far identified, including PGE₂, F_2α, D₂, thromboxane A₂ and their metabolites.PGX is less active in contracting rat fundic strip, chick rectum, guinea pig ileum and guinea pig trachea than are PGG₂ and PGH₂. PGX does not contract the rat colon.PGX is unstable in aqueous solution and its anti-aggregating activity disappears within 0.25 min on boiling or within 10 min at 37° C.As an inhibitor of human platelet aggregation induced $\text{in vitro}$ by arachidonic acid PGX was 30 times more potent than PGE₁. The enzymic formation of PGX is inhibited by 15-hydroperoxy arachidonic acid (IC₅₀ = 0.48 μg/ml), by spontaneously oxidised arachidonic acid (IC₅₀ <100 μg/ml) and by tranylcypromine (IC₅₀ = 160 μg/ml).We conclude that a balance between formation by arterial walls of PGX which prevents platelet aggregation and release by blood platelets of prostaglandin endoperoxides which induce aggregation is of the utmost importance for the control of thrombus formation in vessels.     

Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis

Homogenates of phagocytosing polymorphonuclear leukocytes obtained from rabbit peritoneum were incubated with the prostaglandin endoperoxides PGG₂ or PGH₂. After 2 min at 0°C, incubation mixtures contained an increased rabbit aorta contracting activity. Ether extracts of incubation mixtures contained a substance which contracted the superfused strips of rabbit aorta and coeliac artery and had a half life which was similar to thromboxane A₂. The generation of thromboxane A₂-like activity from PG endoperoxides was prevented by boiling the homogenate prior to incubation, or by pretreatment with benzydamine, a drug which blocks thromboxane formation in platelets. Production of thromboxane A₂-like material by leukocyte homogenates was compared with platelet microsomal thromboxane synthetase.     

Glutathione promotes prostaglandin H synthase (cyclooxygenase)-dependent formation of malondialdehyde and 15(S)-8-iso-prostaglandin F2α

Prostaglandin (PG) H synthases (PGHS) or cyclooxygenases (COX) catalyse the peroxidation of arachidonic acid (AA) to PGG₂ and PGH₂ which are further converted to a series of prostaglandins and thromboxane A₂. Here, we report that GSH promotes concomitant formation of the current oxidative stress biomarkers malondialdehyde (MDA) and 15(S)-8-iso-prostaglandin F_2α from AA via PGHS. This illustrates an uncommon interplay of enzymatic and chemical reactions to produce species that are considered to be exclusively produced by free-radical-catalysed reactions. We propose mechanisms for the PGHS/AA/GSH-dependent formation of MDA, 15(S)-8-iso-prostaglandin F_2α and other F₂-isoprostanes. These mechanisms are supported by clinical observations.     

Spectroelectrochemical characterization of pain biomarkers

This article reports the first electrochemical characterization of pain biomarkers that include arachidonic acid (AA), prostaglandin G₂ (PGG₂), and cyclooxygenase 2 (COX-2). These biomarkers are mediators of pathophysiology of pain, inflammation, and cell proliferation in cancer. The article also reports the development of an electrochemical immunosensor for monitoring these pain biomarkers. The results revealed that direct electron transfer between AA metabolites and the electrode could be easily monitored and that an enzyme-modified electrode dramatically enhanced bioelectrocatalytic activity toward AA. Cyclic voltammetric analysis of AA revealed a concentration-dependent anodic current with a slope of 2.37 and a limit of detection (LOD) of 0.25 nM. This unique AA/gold electrode electron transfer provides a good electrochemical sensing platform for prostaglandin H₂ (PGH₂) as the basis for quantitation of pain. An amperometric signal intensity of a COX-2 antibody-modified gold electrode was linear with COX-2 concentration in the range of 0.1-0.5 μg/ml and an LOD of 0.095 μg/ml. The results also revealed a linear correlation of the concentration of PGG₂ with an LOD of 0.227 μM.     

Identification of the major urinary metabolite of thromboxane B2 in the monkey

Thromboxane B₂ (TxB₂) was biosynthesized from prostaglandin endoperoxides (PGG₂, PGH₂) using guinea pig lung microsomes and infused into an unanesthetized monkey. Urine was collected and TxB₂ metabolites were isolated by reversed phase partition chromatography and high performance liquid chromatography. A major metabolite (TxB₂-M) was found to be excreted in greater than two-fold abundance relative to other metabolites. Its structure was determined by gas chromatography-mass spectrometry to be dinorthromboxane B₂. $\text{In vitro}$ incubation of TxB₂ with rat liver mitochondria yielded a C₁₈ derivative with a mass spectrum identical to that of TxB₂-M, substantiating that the major urinary metabolite of TxB₂ in the monkey is a product of a single step of β-oxidation.     

Prostaglandins H1 and H2. Convenient biochemical synthesis and isolation. Further biological and spectroscopic characterization

An easy biochemical preparation of the prostaglandin endoperoxides, PGH₁ and PGH₂, is described. Both of the endoperoxides are potent contractors of isolated gerbil colon smooth muscle. Contracture with PGH₂ is about equal to that caused by the standard, PGE₁, while contracture with PGH₁ is about half of that caused by PGE₁. PGH₁ was found to inhibit platelet aggregation induced by PGH₂ and is about 1/10 as potent a stimulator of cAMP accumulation as is PGE₁. The mass spectra of the methyl esters of both PGH₁ and PGH₂ were obtained, as were the infrared spectra of the two compounds. The nuclear magnetic resonance spectrum of PGH₂ is characterized by signals at 4.58 δ and 4.47 δ for the C-9 and C-11 protons, respectively.     

Role of prostaglandin endoperoxides in the serum thiobarbituric acid reaction

In the presence of heme and reduced glutathione, prostaglandin (PG) endoperoxides underwent rapid conversion to malondialdehyde and 12l-hydroxy-5,8,10-heptadecatrienoic acid. In addition, PG endoperoxides as well as lipid peroxides produced malondialdehyde to yield a red pigment during the thiobarbituric acid reaction with different efficiencies. The relative rates of the reaction were: 1,1,3,3-tetraethoxypropane, 100; PGG₂, 55; PGH₂, 32; and 15-hydroperoxyarachidonic acid, 6. The thiobarbituric acid reactive materials in rabbit serum decreased by 25–60%, after intravenous administration of aspirin (a cyclo-oxygenase inhibitor) and with a concomitant decline of serum PG levels. These results, taken together, suggested that serum thiobarbituric acid values, considered to be an indicator of lipid peroxide levels, were to a significant extent due to PG endoperoxides and their derivatives.     

Conversions of prostaglandin endoperoxides by prostacyclin synthase from pig aorta

Partially purified prostacyclin synthase from pig aorta converted the prostaglandin (PG) endoperoxide PGH₂ to prostacyclin (PGI₂), and PGH₁ to 12-hydroxy-8,10-heptadecadienoic acid (HHD). Both reactions were inhibited by 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid (15-HP) in a dose-dependent fashion. However, the reactions PGH₂ → PGI₂ and PGH₁ → HHD appeared to differ: substrate availability was rate limiting in the latter reaction, while the enzyme became rapidly saturated with PGH₂ and a steady rate of prostacyclin formation was observed at higher substrate levels.     

Metabolism and effect of prostaglandin H2 in adipose tissue

Prostaglandin H₂ (PGH₂) inhibited noradrenaline induced cyclic AMP accumulation in isolated rat fat cells in a dose-dependent manner. IC₅₀ was 10 – 25 ng/ml both in the absence and in the presence of theophylline. The degree of inhibition produced by PGH₂ increased with time of incubation. A stable PGH₂ analog did not inhibit cyclic AMP accumulation. PGH₂ was rapidly converted by isolated fat cells to PGD₂, PGE₂ and PGH_2α, but no formation of thromboxane B₂ was found either or . PGE₂ was a more potent inhibitor than PGH₂ of noradrenaline induced cyclic AMP accumulation. PGD₂ enhanced cyclic AMP accumulation in a limited concentration interval, while PGF_2α was essentially uneffective.Our results suggest that PGH₂ is an inhibitor of cyclic AMP formation in isolated rat fat cells only after conversion to PGE₂. A physiological role for PGH₂ as a modulator of lipolysis is considered unlikely.     

Biological activities of prostaglandin H1 analogs

The influences of epoxymethano and epoxycarbonyl analogs of PGH₁ on washed rabbit platelets, isolated smooth muscles and perfused heart preparations were investigated. On washed rabbit platelets, 11,9-epoxy-methano and 11,9-epoxycarbonyl PGH₁ produced a platelet aggregation whereas 9,11-epoxymethano and 9,11-epoxy-carbonyl PGH₁ produced an inhibition of arachidonic acid-induced platelet aggregation. On isolated rabbit thoracic aorta strips, 9,11-epoxycarbonyl PGH₁ showed strong contracting activity (5 times as active as 11,9-epoxy-methano PGH₂ and 31 times as active as PGH₂). All the analogs of PGH₁ caused contraction of guinea pig tracheal muscle and caused an increase of perfusion pressure in guinea pig heart, though 11,9-epoxymethano and epoxy-carbonyl PGH₁ were far more active than 9,11-epoxymethano and epoxycarbonyl PGH₁. Differences in biological activities between 11,9-epoxymethano and epoxycarbonyl PGH₁, and 9,11-epoxymethano and epoxycarbonyl PGH₁ indicate that the orientation of functional groups at C₉ and C₁₁ influences biological activities.     

The effect of PGH2 on blood flow in the canine renal and superior mesenteric vascular beds

Effects of the prostaglandin endoperoxide, PGH₂, were investigated in the renal and superior mesenteric vascular beds in anesthetized dogs. Vascular effects of a stable PGH₂ analog were also studied in the intestine. Blood flow was measured with electromagnetic flowmeters and vasoactive hormones were administered by close intra-arterial injection. Authentic PGH₂ increased blood flow in the kidney and intestine in a dose-related manner. Mesenteric blood flow was reduced by the PGH₂ analog in a dose-dependent fashion which was similar to the vasoconstrictor activity of norepinephrine in this organ. PGH₂ is biologically unstable and the type and activity of its metabolic products may vary in different regional vascular beds. Most of the known products of PGH₂ metabolism in the kidney are vasodilators whereas in the intestine both vasodilator and vasoconstrictor metabolites are formed. It has been suggested that the vascular activity of PGH₂ in an organ is dependent on the predominant type and activity of specific terminal enzymes that convert PGH₂ to its various vaso-active products.     

Studies on membrane-associated prostaglandin E synthase-2 with reference to production of 12L-hydroxy-5,8,10-heptadecatrienoic acid (HHT)

Membrane-associated prostaglandin (PG) E synthase (mPGE synthase)-2 catalyzes the conversion of PGH₂ primarily to PGE₂. The enzyme is activated by various sulfhydryl reagents including dithiothreitol, dihydrolipoic acid, and glutathione, and it is different from mPGE synthase-1 and cytosolic PGE synthase, both of which require specifically glutathione. Recently, other investigators reported that their preparation of mPGE synthase-2 containing heme converted PGH₂ to 12L-hydroxy-5,8,10-heptadecatrienoic acid (HHT) rather than to PGE₂ [T. Yamada, F. Takusagawa, Biochemistry 46 (2007) 8414-8424]. As we examined presently, the heme-bound enzyme expressed and purified according to their method synthesized HHT from PGH₂, but also PGE₂ in a decreased amount. Whereas the PGE synthase activity was completely lost at 50 °C for 5 min, the HHT synthase activity remained even at 100 °C for 5 min. In contrast, when the heme-bound enzyme was purified in the presence of dithiothreitol, only PGE₂ was produced, but essentially no HHT was detected. Thus, native mPGE synthase-2 enzymatically catalyzes only the conversion of PGH₂ to PGE₂, but not to HHT, and heme is not involved in this reaction.